The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Final progression-free survival analysis of phase II study with the combination therapy of DFP-14323, protease inhibitor, and low-dose afatinib as first-line therapy for common EGFR mutation–positive NSCLC.
 
Hiroshige Yoshioka
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Delta-Fly Pharma; Kyowa Kirin Co., Ltd.; Lilly; MSD K.K; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - Delta-Fly Pharma
 
Masahide Mori
No Relationships to Disclose
 
Nobuyuki Katakami
No Relationships to Disclose
 
Toshihide Yokoyama
No Relationships to Disclose
 
Hiroyasu Kaneda
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Merck; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Research Funding - Lilly Japan
 
Hirotaka Matsumoto
No Relationships to Disclose
 
Toru Kumagai
No Relationships to Disclose
 
Kouji Yamamoto
Consulting or Advisory Role - Delta-Fly Pharma
 
Cheng-long Huang
No Relationships to Disclose